Growing investments in the field of breast imaging and rising occurrences of breast cancer are among the significant factors influencing the market growth.
According to a recent analysis by Emergen Research, the global mammography system market is anticipated to reach USD 4,255.3 Million by 2027. Due to the increased incidence of breast cancer and the use of mammograms to detect tumours, lesions, and other abnormalities in the breasts, the market for mammography systems is seeing significant demand. With more than 2 million new instances of breast cancer in 2018, breast cancer is the most frequent cancer form among women. In North America, Japan, and Sweden, the breast cancer survival rate is around 80%; in middle-income countries, it is close to 60%; and in low-income countries, it is less than 40%.
X-rays and other low-energy ionising radiations are used in mammography systems to look for cancer that hasn’t yet been diagnosed. Over the past ten years, healthcare institutions have implemented a wide range of screening initiatives to lower cancer-related mortality rates globally. The use of routine screening mammograms for women over the age of 40 is advised by healthcare organisations like the American Medical Association, the National Cancer Institute, and the National Comprehensive Cancer Network in order to increase cancer screening participation and lower the risk of developing breast cancer.
The technology, end-user, and geographic segments have been established for the worldwide mammography systems market. The global market for mammography systems has been divided into analogue and digital mammography systems based on technology. In 2016, a sizable portion of the market was dominated by digital mammography systems. The section of digital mammography systems is further subdivided into 2-D and 3-D mammography systems. During the projected period, the market is likely to be driven by the high prevalence of breast cancer and the growing geriatric population. In 2030, there will probably be 2.1 million new cases of breast cancer, according to the World Cancer Research Fund.
In terms of revenue, the full-field digital mammography (FFDM) system for digital mammography held the biggest market share in 2019. It provides the benefit of magnification and picture manipulation to properly locate and examine the anomalies. Additionally, the photos can be electronically sent to radiologists, breast surgeons, and other medical professionals for study.
Key participants include Hologic, Siemens Healthineers, Metaltronica, Philips Healthcare, Fujifilm, Mindray Medical International Limited, Planmed Oy, GE Healthcare, and IMS Sri, among others.
The market for mammography systems’ breast tomosynthesis systems will expand by 9.4% from 2017 to 2027, driven by rising mammography technology usage and better clinical results. Comparatively speaking, the technology offers improved efficacy and higher diagnostic accuracy than other breast imaging modalities. These elements are predicted to encourage sector expansion in the upcoming years.
Due to ongoing developments in technology, the market for 3D mammography technology reached USD 470 million in 2020. Thus, expanding DBT device acceptability and rising usage of cutting-edge breast imaging techniques are both helping to the market’s expansion.
Due to an increase in breast screening operations in hospitals and the availability of modern mammography systems, the hospitals end-use market exceeded USD 1.2 billion in 2020. Women of all ages can receive complete breast care services from the breast imaging departments of hospitals. A patient-centered approach to care and the utilisation of multidisciplinary high technology are the variables affecting the segment expansion. Additionally, the demand for the product will be driven in the upcoming years by the availability of specialised radiologists in hospitals and improved clinical outcomes.
Emergen Research has segmented the global Fc fusion protein on the basis of type, therapeutic area, application, end-use, and region:
Type Outlook (Revenue, USD Billion; 2018–2028)
- Biosimilar Drugs
- Brands Drugs
Therapeutic Area Outlook (Revenue, USD Billion; 2018–2028)
- Eye Diseases
- Autoimmune Disease
Application Outlook (Revenue, USD Billion; 2018–2028)
- In Vitro
- Flow Cytometry
- Binding Assays
- Microarray Technologies
- In Vivo
- Bio-therapeutic Drugs
End-Use Outlook (Revenue, USD Billion; 2018–2028)
- Ophthalmic Hospitals
- Oculoplastic Clinics